, Volume 77, Issue 15, pp 1677–1686 | Cite as

Lonoctocog Alfa: A Review in Haemophilia A

Adis Drug Evaluation


Lonoctocog alfa (rVIII-SingleChain; Afstyla®) is a novel single-chain recombinant factor VIII (FVIII) molecule, with a truncated B-domain and the heavy and light chains covalently linked to form a stable and homogenous drug that binds with high affinity to von Willebrand factor (VWF). Intravenous lonoctocog alfa is approved for the prophylaxis and treatment of bleeding in patients with haemophilia A in several countries worldwide. In two pivotal, multicentre trials, lonoctocog alfa was effective in the treatment of bleeding episodes and as prophylaxis, including for perioperative management in adults, adolescents and children. In terms of haemostatic efficacy in controlling bleeding episodes, overall treatment and investigator-assessed success rates were high across all age groups, with the majority of these bleeds controlled with a single injection of lonoctocog alfa. Low median spontaneous, overall and traumatic annualized bleeding rates were evident with prophylactic lonoctocog alfa regimens in both trials. Lonoctocog alfa was generally well-tolerated, with very low rates of injection-site reactions. No previously treated patient experienced an anaphylactic reaction or developed an inhibitor. In conclusion, lonoctocog alfa is an effective and generally well-tolerated alternative to conventional FVIII products for the treatment and prophylaxis of bleeding, including in the surgical setting, in adults, adolescents and children with haemophilia A.



During the peer review process, the manufacturer of lonoctocog alfa was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with Ethical Standards


The preparation of this review was not supported by any external funding.

Conflict of interest

Zaina T. Al-Salama and Lesley J. Scott are salaried employees of Adis/Springer, are responsible for the article content and declare no relevant conflicts of interest.

Additional information about this Adis Drug Review can be found at http://www.medengine.com/Redeem/CBD8F060224F2E65.


  1. 1.
    Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1–47.CrossRefPubMedGoogle Scholar
  2. 2.
    Manco-Johnson MJ, Riske B, Kasper CK. Advances in care of children with hemophilia. Semin Thromb Hemost. 2003;29(6):585–94.CrossRefPubMedGoogle Scholar
  3. 3.
    Srivastava A. Haemophilia care—beyond the treatment guidelines. Haemophilia. 2014;20(Suppl 4):4–10.CrossRefPubMedGoogle Scholar
  4. 4.
    Mahlangu J, Kuliczkowski K, Karim FA, et al. Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A. Blood. 2016;128(5):630–7.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Zollner S, Raquet E, Claar P, et al. Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII. Thromb Res. 2014;134(1):125–31.CrossRefPubMedGoogle Scholar
  6. 6.
    Schulte S. Pioneering designs for recombinant coagulation factors. Thromb Res. 2011;128(Suppl 1):S9–12.CrossRefPubMedGoogle Scholar
  7. 7.
    Schulte S. Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII. Thromb Res. 2013;131(Suppl 2):S2–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Stasyshyn O, Khayat CD, Iosava G, et al. Safety, efficacy and pharmacokinetics of rVIII-SingleChain in children with severe hemophilia A: results of a multicenter clinical trial. J Thromb Haemost. 2017;15(4):636–44.CrossRefPubMedGoogle Scholar
  9. 9.
    Zollner SB, Raquet E, Müller-Cohrs J, et al. Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII. Thromb Res. 2013;132(2):280–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Delignat S, Repesse Y, Navarrete AM, et al. Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia A. Haemophilia. 2012;18(2):248–54.CrossRefPubMedGoogle Scholar
  11. 11.
    Pipe SW, Montgomery RR, Pratt KP, et al. Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A. Blood. 2016;128(16):2007–16.CrossRefPubMedGoogle Scholar
  12. 12.
    CSL Behring GmbH. Afstyla® [antihemophilic factor (recombinant), single chain for intravenous injection, powder and solvent for injection]: US prescribing information. 2016. http://labeling.cslbehring.com. Accessed 4 Sept 2017.
  13. 13.
    CSL Behring GmbH. Afstyla® (lonoctocog alfa): EU summary of product characteristics. 2016. https://ec.europa.eu/. Accessed 04 Sept 2017.
  14. 14.
    US FDA. BLA Clinical review memorandum. 2015. https://www.fda.gov/. Accessed 4 Sept 2017.
  15. 15.
    US FDA. Clinical pharmacology BLA review. 2015. http://www.fda.gov/. Accessed 4 Sept 2017.
  16. 16.
    European Medicines Agency. Afstyla (lonoctocog alfa): EU assessment report. 2016. http://www.ema.europa.eu/. Accessed 4 Sept 2017.
  17. 17.
    Dasgupta S, Repesse Y, Bayry J, et al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood. 2007;109(2):610–2.CrossRefPubMedGoogle Scholar
  18. 18.
    Klamroth R, Simpson M, von Depka-Prondzinski M, et al. Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate®) in patients with severe haemophilia A. Haemophilia. 2016;22(5):730–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Zhang Y, Roberts J, Tortorici M, et al. Population pharmacokinetics of recombinant coagulation factor VIII-SingleChain in patients with severe hemophilia A. J Thromb Haemost. 2017;15(6):1106–14.CrossRefPubMedGoogle Scholar
  20. 20.
    Mannucci PM. Half-life extension technologies for haemostatic agents. Thromb Haemost. 2015;113(1):165–76.CrossRefPubMedGoogle Scholar
  21. 21.
    Peyvandi F, Oldenburg J, Friedman KD. A critical appraisal of one-stage and chromogenic assays of factor VIII activity. J Thromb Haemost. 2016;14(2):248–61.CrossRefPubMedGoogle Scholar
  22. 22.
    Veldman A, Feussner A, Kalina U, et al. rVIII-SingleChain plasma activity can be measured using both the one-stage and the chromogenic substrate assay: results from an international field study [abstract plus poster]. In: 61st annual meeting of the society of thrombosis and hemostasis Research. 2017.Google Scholar
  23. 23.
    Kitchen S, Kershaw G, Tiefenbacher S. Recombinant to modified factor VIII and factor IX—chromogenic and one-stage assays issues. Haemophilia. 2016;22(Suppl 5):72–7.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations